Good morning, it's Paul & Jack here with the SCVR for Monday.

Agenda -

Paul's Section:

Card Factory (LON:CARD) - a meaningful Director buy (of £107k) reinforces my view that things seem to be improving for this greetings card retailer, following a sound recent trading update. Although bank debt remains a concern, due to the risk of an equity raise being required.

Billington Holdings (LON:BILN) - profit warning for FY 12/2021, due to contract delays, and supply chain issues. WH Ireland halves profit forecast for 2021. On the upside, outlook for 2022 is good, and balance sheet is strong. Overall though, I see little attraction to this share.

Nightcap (LON:NGHT) - awful results for FY 06/2021, mainly due to massive £3.8m share option charge (how can that be justified at this early stage?), and IPO costs. Balance sheet looks quite weak - the big cash pile seems to be offset by bank borrowings + stretched creditors. Overall, I think this looks significantly over-valued, having a premium for newness and roll-out potential.

Totally (LON:TLY) - low margin healthcare outsourcing company, has produced decent interim results. This share looks quite interesting, with over £5m annualised EBITDA, a number which survives my close inspection! The cash on the balance sheet has come from favourable payment terms with the NHS, so shouldn't be seen as surplus cash. Overall, I quite like this share, looks an interesting business that's now performing well.

Jack's Section:

to follow


Explanatory notes -

A quick reminder that we don’t recommend any stocks. We aim to review trading updates & results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it's anybody's guess what direction market sentiment will take & nobody can predict the future with certainty. We are analysing the company fundamentals, not trying to predict market sentiment.

We stick to companies that have issued news on the day, with market caps up to about £700m. We avoid the smallest, and most speculative companies, and also avoid a few specialist sectors (e.g. natural resources, pharma/biotech).

A key assumption is that readers DYOR (do your own research), and make your own investment decisions. Reader comments are welcomed - please be civil,…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here